1. Home
  2. EMF vs MYGN Comparison

EMF vs MYGN Comparison

Compare EMF & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Templeton Emerging Markets Fund

EMF

Templeton Emerging Markets Fund

SELL

Current Price

$21.75

Market Cap

335.9M

Sector

Finance

ML Signal

SELL

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

SELL

Current Price

$4.08

Market Cap

372.1M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
EMF
MYGN
Founded
1987
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
335.9M
372.1M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
EMF
MYGN
Price
$21.75
$4.08
Analyst Decision
Hold
Analyst Count
0
9
Target Price
N/A
★ $4.05
AVG Volume (30 Days)
24.3K
★ 2.0M
Earning Date
01-01-0001
11-02-2026
Dividend Yield
★ 6.16%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $771,400,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$5.47
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 2.33
52 Week Low
$16.12
$2.74
52 Week High
$24.70
$8.59

Technical Indicators

Market Signals
Indicator
EMF
MYGN
Relative Strength Index (RSI) 40.79 53.52
Support Level $20.91 $2.89
Resistance Level $22.97 $4.89
Average True Range (ATR) 0.46 0.24
MACD -0.07 -0.02
Stochastic Oscillator 7.41 22.78

Price Performance

Historical Comparison
EMF
MYGN

About EMF Templeton Emerging Markets Fund

Templeton Emerging Markets Fund is a closed-end management investment company that seeks long-term capital appreciation by investing mainly in emerging country equity securities under normal market conditions. It invests across various sectors, including Pharmaceuticals, Beverages, Broadline Retail, Metals & Mining, Banks, Food Products, Semiconductors & Semiconductor Equipment, Insurance, Entertainment, and others.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Share on Social Networks: